AR046793A1 - Derivados de pirazol, antagonistas del receptor de la orexina - Google Patents
Derivados de pirazol, antagonistas del receptor de la orexinaInfo
- Publication number
- AR046793A1 AR046793A1 ARP040104839A ARP040104839A AR046793A1 AR 046793 A1 AR046793 A1 AR 046793A1 AR P040104839 A ARP040104839 A AR P040104839A AR P040104839 A ARP040104839 A AR P040104839A AR 046793 A1 AR046793 A1 AR 046793A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- atom
- general formula
- partially
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 17
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- SDCMHPPKMQZPPJ-UHFFFAOYSA-N 3-phenyl-4h-quinazoline Chemical compound C1=NC2=CC=CC=C2CN1C1=CC=CC=C1 SDCMHPPKMQZPPJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- -1 preferably an N Chemical group 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos antagonistas del receptor de la orexina de la fórmula general (1), Ar representa un grupo fenilo o un anillo heteroaromático de 5 o 6 miembros que contiene 1-3 heteroátomos, preferiblemente un átomo de N, un átomo de O o un átomo de S, donde cualquiera de estos anillos puede estar opcionalmente mono o polisustituidos con un átomo de halógeno, un grupo alquilo C1-4, un grupo alcoxilo C1-4, un grupo hidroxilo, un grupo ciano, un grupo trihalógenometilo, un grupo amino o un grupo amino sustituido con uno o dos grupos alquilo C1-4; Y representa un grupo -CH2-; X representa un átomo de S, un átomo de O, un grupo -NH-, un grupo -N(alquilo C1-4), un grupo -CH2-, un grupo -(S=O)- o un grupo -SO2-; o X e Y representan juntos un grupo -CH=CH- con geometría cis o trans, A representa una porción con un anillo heteroaromático de 5 o 6 miembros que contiene, en la posición orto, meta o para, dos valencias libres, que está opcionalmente mono o polisustituido con un átomo de halógeno, un grupo alquilo C1-4 o un grupo alcoxilo C1-4; o con un anillo de cicloalquilo de 5 o 6 miembros parcial o completamente saturado, opcionalmente mono o polisustituido con un átomo de halógeno, un grupo alquilo C1-4 o un grupo alcoxilo C1- 4; o con un anillo heteroaromático o heterocíclico parcial o completamente saturado que contiene 1-3 heteroátomos, preferiblemente un átomo de N, O o S, que está opcionalmente mono o polisustituido con un átomo de halógeno, un grupo alquilo C1-4 o un grupo alcoxilo C1-4; R1 representa un grupo bencilo, alquilo C1-4, hidroxialquilo C1-4, alcoxicarbonilalquilo C3-8,alquilcarbonilo C2-7, carboxialquilo C2-7, aminocarbonil-C1-4-alquilo, C1-3-alquilaminocarbonil-C1-4-alquilo, amino-C1-4-alquilo, C1-3-alquilamino-C1-4-alquilo, morfolino C1-4-alquilo, o morfolinocarbonil-C1-4-alquilo, o un grupo fenilo opcionalmente sustituido con uno o más átomos de halógenos; R2 representa uno de los siguientes grupos, que está opcionalmente sustituido con uno o más átomos de halógenos; un grupo hidroxilo, un grupo alquilo C1-4, un grupo trihalógenometilo, un grupo tio-C1-4-alquilo, un grupo amino, un grupo -(C=O)-NH-C1-4-alquilo o cicloalquilo; un grupo fenilo, un grupo feniletilo, un grupo naftilo, un grupo indanilo o indenilo, un grupo cíclico de 5 o 6 miembros, heteroaromático o parcial o completamente saturado que contiene 1-3 heteroátomos idénticos o diferentes, preferiblemente un átomo de N, O o S, un grupo que contiene una porción heteroaromática bicíclica o un heteroanillo bicíclico parcial o completamente saturado con 1, 2 o 3 heteroátomos idénticos o diferentes, preferiblemente un átomo de N, O o S; R3 representa un átomo de H o un grupo alquilo C1-4, R2 y R3, junto con el átomo de N al que están unidos, representan un anillo de 6 miembros parcial o completamente saturado opcionalmente sustituido con un grupo fenilo o bencilo sustituido; R5 representa un átomo de halógeno, un átomo de H, un grupo alquilo C1-4, un grupo tioalquilo C1-4, un grupo alcoxilo C1-4, y sus sales, isómeros y solvatos, las composiciones farmacéuticas que los contienen y la aplicación terapéutica de los mismos. Un proceso para preparar los compuestos de fórmula general (1), y sus sales, isómeros y solvatos, donde a) se transforma el ácido de fórmula general (2) en su derivado activo, y se lo hace reaccionar con la amina de fórmula general (3) NHR2R3 o b) se hace reaccionar un derivado de clorometilo de fórmula general (4) con una amida de fórmula general (5) y, si se lo desea, se libera el compuesto resultante de su sal, o se lo transforma en una sal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0304101A HUP0304101A3 (en) | 2003-12-22 | 2003-12-22 | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046793A1 true AR046793A1 (es) | 2005-12-21 |
Family
ID=89981868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104839A AR046793A1 (es) | 2003-12-22 | 2004-12-22 | Derivados de pirazol, antagonistas del receptor de la orexina |
Country Status (9)
Country | Link |
---|---|
US (2) | US7659298B2 (es) |
EP (1) | EP1699454B1 (es) |
JP (1) | JP4861829B2 (es) |
AR (1) | AR046793A1 (es) |
AT (1) | ATE438395T1 (es) |
DE (1) | DE602004022458D1 (es) |
HU (1) | HUP0304101A3 (es) |
TW (1) | TWI289558B (es) |
WO (1) | WO2005060959A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1602647B1 (en) * | 2003-03-07 | 2013-10-16 | Santen Pharmaceutical Co., Ltd. | Novel compound having 4-pyridylalkylthio group as substituent |
HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
CN101166733A (zh) * | 2004-10-15 | 2008-04-23 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的吡唑衍生物 |
FR2896799B1 (fr) * | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
CA2657623A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
US8263586B2 (en) | 2007-05-18 | 2012-09-11 | Merck Sharp & Dohme Corp. | OXO bridged diazepan orexin receptor antagonists |
CA2687230A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
ATE540944T1 (de) | 2007-05-23 | 2012-01-15 | Merck Sharp & Dohme | Pyridylpiperidinorexin-rezeptorantagonisten |
RU2479577C2 (ru) | 2007-05-25 | 2013-04-20 | Эбботт Гмбх Унд Ко.Кг | Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2) |
CN102056920A (zh) * | 2008-06-11 | 2011-05-11 | 埃科特莱茵药品有限公司 | 用作食欲素受体拮抗剂的四唑化合物 |
RU2013132930A (ru) * | 2010-12-17 | 2015-01-27 | Тайсо Фармасьютикал Ко., Лтд. | Производное пиразола |
KR101873083B1 (ko) * | 2011-02-18 | 2018-06-29 | 이도르시아 파마슈티컬스 리미티드 | 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체 |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
AU2013217323A1 (en) | 2012-02-07 | 2014-08-28 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
LT3414241T (lt) | 2016-02-12 | 2022-08-25 | Astrazeneca Ab | Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai |
EP3454857A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
PE20211700A1 (es) * | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
LU68238A1 (es) * | 1973-08-16 | 1975-05-21 | ||
DE3835732A1 (de) * | 1988-10-20 | 1990-04-26 | Thomae Gmbh Dr K | Heterocyclisch substituierte 3-hydroxy-glutarsaeuren und ihre derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
GB9708340D0 (en) * | 1997-04-25 | 1997-06-18 | Univ Napier | Organic blue light emitting materials for use in electroluminescent display devices |
ES2196806T3 (es) * | 1998-05-08 | 2003-12-16 | Smithkline Beecham Plc | Derivados de fenilurea y de feniltiourea. |
PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
-
2003
- 2003-12-22 HU HU0304101A patent/HUP0304101A3/hu unknown
-
2004
- 2004-12-15 WO PCT/HU2004/000117 patent/WO2005060959A1/en not_active Application Discontinuation
- 2004-12-15 DE DE602004022458T patent/DE602004022458D1/de active Active
- 2004-12-15 EP EP04806274A patent/EP1699454B1/en not_active Not-in-force
- 2004-12-15 JP JP2006546344A patent/JP4861829B2/ja not_active Expired - Fee Related
- 2004-12-15 AT AT04806274T patent/ATE438395T1/de not_active IP Right Cessation
- 2004-12-17 TW TW093139247A patent/TWI289558B/zh not_active IP Right Cessation
- 2004-12-22 AR ARP040104839A patent/AR046793A1/es not_active Application Discontinuation
-
2006
- 2006-06-21 US US11/425,583 patent/US7659298B2/en not_active Expired - Fee Related
-
2010
- 2010-02-03 US US12/699,231 patent/US20110059964A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110059964A1 (en) | 2011-03-10 |
HUP0304101A3 (en) | 2008-10-28 |
WO2005060959A8 (en) | 2006-01-12 |
US7659298B2 (en) | 2010-02-09 |
JP2007519630A (ja) | 2007-07-19 |
EP1699454B1 (en) | 2009-08-05 |
TWI289558B (en) | 2007-11-11 |
TW200526632A (en) | 2005-08-16 |
HUP0304101A2 (hu) | 2005-09-28 |
EP1699454A1 (en) | 2006-09-13 |
HU0304101D0 (en) | 2004-03-29 |
US20070021459A1 (en) | 2007-01-25 |
WO2005060959A1 (en) | 2005-07-07 |
DE602004022458D1 (de) | 2009-09-17 |
JP4861829B2 (ja) | 2012-01-25 |
ATE438395T1 (de) | 2009-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046793A1 (es) | Derivados de pirazol, antagonistas del receptor de la orexina | |
AR127309A2 (es) | Derivados de piridazinona | |
AR033306A1 (es) | Compuestos | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
AR046938A1 (es) | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
AR030553A1 (es) | Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados | |
AR021354A1 (es) | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica | |
PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR105122A1 (es) | INHIBIDORES DE METALO-b-LACTAMASA | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
AR078786A1 (es) | Derivados de la cromenona | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR022820A1 (es) | Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica. | |
AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
PE20200664A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |